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with cardiac events: a retrospective analysis
of the UPLIFT® trial
Donald P Tashkin1*, Inge Leimer2, Norbert Metzdorf2 and Marc Decramer3Abstract
Background: Tiotropium is an anticholinergic bronchodilator for symptom relief and reducing exacerbations with
an established safety profile in patients with chronic obstructive pulmonary disease (COPD). Using data from the
4-year Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT®) study, we re-evaluated
the safety of tiotropium HandiHaler® in patients who experienced recent myocardial infarction (MI), heart failure or
unstable rhythm disorder during the study.
Methods: A post-hoc analysis of all-cause mortality and serious cardiac adverse events (cardiac SAEs), including
cardiac deaths and death unknown, was conducted in patients who had experienced cardiac arrhythmia, MI or
cardiac failure during UPLIFT® and who completed the study. Descriptive analyses were performed.
Results: Most patients experiencing cardiac events, for which they would have been excluded at baseline, remained in
the trial. Kaplan-Meier analyses revealed a trend to later occurrence of cardiac SAEs with tiotropium HandiHaler® versus
placebo. Patients who experienced a cardiac event and continued in UPLIFT® were not found to be at subsequently
increased risk of all-cause mortality or cardiac SAEs with tiotropium treatment. Evaluation of deaths by major adverse
cardiac events composite endpoints also showed that patients treated with tiotropium were not at increased risk of
mortality or cardiac SAEs compared with placebo.
Conclusions: Risk of cardiac events, mortality or SAEs was not increased by tiotropium in patients experiencing cardiac
events for which they would have been excluded at study baseline. The findings support the cardiac safety of
tiotropium HandiHaler® in patients with COPD.
Keywords: UPLIFT®, Cardiac safety, Tiotropium HandiHaler®, COPDIntroduction
Tiotropium is a once-daily maintenance anticholinergic
bronchodilator for the relief of symptoms and reducing ex-
acerbations in patients with chronic obstructive pulmonary
disease (COPD) [1-3]. Two formulations have been devel-
oped (SPIRIVA®, Boehringer Ingelheim, Ingelheim am
Rhein, Germany): tiotropium HandiHaler® 18 μg once daily,
a dry powder inhaler; and tiotropium Respimat® 5 μg (two
puffs of 2.5 μg) once daily. Respimat® was developed to pro-
vide a more efficient drug delivery system, with increased
deposition in the lung to allow for a reduced nominal dose* Correspondence: dtashkin@mednet.ucla.edu
1Department of Medicine, David Geffen School of Medicine at UCLA, Los
Angeles, CA, USA
Full list of author information is available at the end of the article
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creativecommons.org/publicdomain/zero/1.0/versus Handihaler®, a delivered dose independent of in-
spiratory effort and ease of co-ordination of actuation
and inhalation [4,5]. Pharmacokinetic analysis indicates
that systemic exposure is similar for tiotropium 18 μg
via HandiHaler® and tiotropium 5 μg via Respimat®
[6,7]; clinical studies have also shown that the Tiotropium
Respimat® is non-inferior to HandiHaler® for lung func-
tion outcomes and rescue medication use [6,7], as well as
exacerbation risk [8].
A reduction in mortality versus placebo was observed in
the Understanding Potential Long-term Impacts on Func-
tion with Tiotropium (UPLIFT®) study, a randomised,
double-blind trial in which tiotropium HandiHaler® was
compared with placebo in almost 6000 patients over a
period of 4 years [9]. In this study, for the protocol-rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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whom vital status information was available, 921 patients
died: 14.4% in the tiotropium group, 16.3% in the placebo
group (hazard ratio: 0.87; 95% confidence interval [CI]:
0.76–0.99) [9]. In line with the findings from UPLIFT®,
other meta-analyses and data reviews have also failed to
find any increases in all-cause mortality in patients with
COPD [10-13].
However, safety concerns were raised when a post-hoc
pooled analysis of three 1-year and one 6-month
placebo-controlled trials found that tiotropium Respi-
mat® 5 μg was associated with a higher number of fatal
events than placebo, although the difference was not
statistically significant. The difference was particularly
found in patients with cardiac rhythm disorders at ran-
domisation [14]. The contribution of a rhythm disorder
to the fatal outcome was uncertain and a causal relation-
ship with tiotropium Respimat® has not been established.
Subsequent systematic reviews and meta-analyses of the
same clinical dataset by different authors have also de-
scribed an increase in mortality associated with Res-
pimat® [15-17]. However, the TIOtropium Safety and
Performance In Respimat® (TIOSPIR™) study found no
difference in mortality with tiotropium Respimat® versus
HandiHaler® with respect to the risk of death, and causes
of death were similar between the groups [8].
The debate surrounding potential differential effects of
HandiHaler® and Respimat® on mortality associated with
tiotropium has led to discussion and re-evaluation of
previous clinical trials in COPD to understand the valid-
ity of the findings. Most recently, the generalisability of
the results of the 4-year UPLIFT® trial comparing tiotro-
pium with placebo was called into question, based on
potential eligibility of a hospitalised patient population
with COPD in New Zealand for UPLIFT® [18]. In their
evaluation of 100 patients who were prescribed tiotro-
pium, the authors concluded that 38% (95% CI: 28.5–
48.3) would have been ineligible for UPLIFT® at the time
of hospital discharge due to recent cardiovascular (CV)
co-morbidity or moderate to severe renal impairment.
While the interpretation of the findings from this study
were challenged by the authors of UPLIFT® [19], it was
recognised that analysis of outcomes of patients experi-
encing cardiac events during the 4-year UPLIFT® study
could add valuable data to the debate on the potential
effects of tiotropium on CV and overall mortality. It has
recently been noted that, in addition to looking at over-
all mortality or composite CV endpoints (such as major
adverse CV events [MACE]), specific cardiac outcomes
(such as myocardial infarction [MI]) should also be con-
sidered, to avoid masking a potential treatment effect on
a particular type of event [20].
Patients experiencing specific recent cardiac events
before the baseline of UPLIFT® were excluded fromparticipation in the trial. Therefore, to evaluate tiotro-
pium HandiHaler® safety in patients with recent cardiac
events, we conducted post-hoc analyses of all-cause mor-
tality and serious cardiac adverse events (cardiac SAEs),
including cardiac deaths and death unknown, in patients
who experienced cardiac arrhythmia, MI or cardiac fail-
ure during the conduct of the UPLIFT® study.
Methods
Full details of the UPLIFT® methodology, including patient
eligibility criteria, have been published previously [9].
Study design and patients
UPLIFT® was a 4-year, randomised, double-blind,
placebo-controlled, parallel-group trial involving patients
with moderate to very severe COPD. All patients gave
written informed consent. The study was approved by
local ethical review boards in each center (see Additional
file 1) and conducted in accordance with the Declaration
of Helsinki.
Patients were excluded from UPLIFT® if they had a
recent history (≤6 months) of MI, any unstable or life-
threatening cardiac arrhythmia or cardiac arrhythmia re-
quiring intervention or a change in drug therapy within
the past year or hospitalisation for heart failure (New
York Heart Association Class III or IV) within the past
year. Patients were randomised to 18 μg of tiotropium
or a matching placebo once daily, delivered through the
HandiHaler® [9]. All respiratory medications, except
other inhaled anticholinergic drugs, were permitted dur-
ing the trial.
After randomisation to treatment groups, clinic visits
occurred at 1 and 3 months, then every 3 months
throughout the 4-year study period. Reports of adverse
events (AEs) were collected at each visit. An independ-
ent data and safety monitoring committee reviewed data
throughout the trial.
Analysis of outcomes in patients experiencing a cardiac
event during the study
Patients who were selected for the post-hoc analyses had
to have experienced a cardiac event with onset during
treatment, but following the first occurrence of the car-
diac event, they did not withdraw from UPLIFT® (either
due to the event or for another reason).
Three types of cardiac events were investigated:
arrhythmia (defined as Standardised Medical Dictionary
for Regulatory Activities [MedDRA] Query [SMQ] Car-
diac arrhythmias sub-SMQ Cardiac arrhythmia terms),
MI (defined as SMQ ischaemic heart disease sub-SMQ
Myocardial Infarction [broad]) and cardiac failure (de-
fined as SMQ Cardiac Failure [narrow]).
Outcomes in patients treated with tiotropium were com-
pared with those receiving placebo. Evaluations included
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of SAEs, cardiac SAEs (using MedDRA version 16.0 defini-
tions) and fatal AEs (FAEs) in the time after the initial car-
diac AE.
For the vital status analysis, FAEs were counted if the
death occurred ≥1 day following the first cardiac event
of interest (arrhythmia, MI or cardiac failure) and within
1440 days of drug start. For the on-treatment analysis,
events were counted if the event occurred ≥1 day follow-
ing the first cardiac event of interest (arrhythmia, MI or
cardiac failure) until cessation of treatment plus 30 days.
A composite endpoint of MACE was included in the
analyses. This endpoint represents fatal events in the
system organ class (SOC) cardiac disorders and SOC
vascular disorders combined with MI (fatal and non-
fatal), stroke (fatal and non-fatal) and the following pre-
ferred terms: sudden death, sudden cardiac death and
cardiac death. For the composite endpoint of fatal
MACE, non-fatal MI and non-fatal stroke were removed.
As a sensitivity analysis, fatal MACE plus the preferred
term ‘death unknown’ was also analysed.Statistical analysis
Descriptive statistical analysis only is presented.Results
Cardiac and mortality outcomes for patients with cardiac
arrhythmia during the UPLIFT® study
In the UPLIFT® trial, 5993 patients were randomly
assigned, 2987 to receive tiotropium and 3006 to receive
placebo. During the study, 400 patients experienced car-
diac arrhythmia: 197 within the placebo arm, and 203 in
the tiotropium treatment arm. Immediately following
the first event, there were 26 discontinuations: 16 within
the placebo arm, 10 in the tiotropium treatment arm.
Kaplan-Meier analysis revealed a trend to later onset of
the initial cardiac arrhythmia event in the tiotropium
group (Figure 1A).
Mean treatment duration after the first cardiac
arrhythmia event was 576.0 days (standard deviation
[SD]: 454.3) for placebo and 518.8 days (SD: 438.0) for
tiotropium patients. Among those patients who were
administered placebo and who experienced a cardiac
arrhythmia during the study, 60.2% (109/181) subse-
quently experienced an SAE and 20.4% (37/181) experi-
enced a cardiac SAE. Similar percentages of patients
experienced SAEs (53.9% [104/193]) and cardiac SAEs
(22.8% [44/193]) in the tiotropium arm (Table 1).
For patients who experienced a cardiac arrhythmia,
FAEs on-treatment affected 19.9% of patients receiving
placebo and 14.5% of patients treated with tiotropium
(Table 1). Vital status analysis was similar, with FAEs oc-
curring slightly more frequently in those who hadreceived placebo (21.0%) compared with tiotropium
(17.6%) (Table 1).
Evaluation of events on-treatment by MACE end-
points did not suggest an increase in events with tiotro-
pium compared with placebo for any of the measures
(Table 1; Additional file 2 also provides a categorical
breakdown of the incidence of fatal MACE, fatal MACE
[including death unknown] and MACE). For patients
with a cardiac arrhythmia, the incidence of on-treatment
MACE was 13.8% in the placebo arm compared with
7.8% in the tiotropium arm. Fatal on-treatment MACE
affected 8.3% of patients receiving placebo and 5.2% of
patients treated with tiotropium; the incidence of fatal
on-treatment MACE including death unknown was 9.9%
and 6.7%, respectively.
Cardiac and mortality outcomes for patients with an MI
during the UPLIFT® study
During the study period, 172 patients experienced an
MI: 92 within the placebo arm, 80 in the tiotropium
arm. Following the first event, there were 41 discontinu-
ations: 24 in the placebo arm, 17 in the tiotropium arm.
Similar to results for cardiac arrhythmia, Kaplan-Meier
analysis of patients with an MI revealed a trend to later
onset of the first MI event in the tiotropium arm com-
pared with the placebo arm (Figure 1B).
Mean treatment duration following the first MI event
was 581.7 days (SD: 444.1) in the placebo arm and
580.6 days (SD: 427.6) in the tiotropium arm. Among
those patients administered placebo who had experienced
an MI during the study, 55.9% subsequently experienced
an SAE and 27.9% experienced a cardiac SAE. In the tio-
tropium arm, 68.3% of patients subsequently experienced
an SAE and 28.6% experienced a cardiac SAE (Table 1).
Vital status FAEs in patients who had experienced an
MI occurred with similar frequency in both those who
had received placebo (16.2%) or tiotropium (12.7%)
(Table 1). On-treatment FAEs were experienced by
16.2% of patients in the placebo arm and by 9.5% of
patients in the tiotropium arm (Table 1).
Evaluation of the events on treatment by MACE end-
points did not suggest an increase in events with tiotro-
pium compared with placebo for any of the measures
(Table 1; Additional file 2). For patients who had an MI,
the incidence of MACE was 16.2% in the placebo arm
compared with 9.5% in the tiotropium arm. Fatal MACE
(and fatal MACE including death unknown) affected
7.4% of patients receiving placebo and 4.8% of patients
treated with tiotropium.
Cardiac and mortality outcomes for patients with cardiac
failure during the UPLIFT® study
During the study period, 397 patients experienced car-
diac failure: 213 within the placebo arm, 184 in the
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Figure 1 Kaplan-Meier analysis of time to onset of the first event. (A) Cardiac arrhythmia, (B) MI and (C) cardiac failure. Time to event is censored
at Day 1440. MI, myocardial infarction, SMQ, Standardised Medical Dictionary for Regulatory Activities Query.
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Table 1 SAEs (on-treatment), FAEs (on-treatment/vital status follow-up) and MACE (on-treatment + 30 days) in patients
with cardiac events during UPLIFT®
Patients with event, n (%)
First event Cardiac arrhythmia* MI* Cardiac failure*
Treatment arm/ Placebo Tiotropium Placebo Tiotropium Placebo Tiotropium
Subsequent event (n = 181) HandiHaler® (n = 68) HandiHaler® (n = 186) HandiHaler®
18 μg (n = 193) 18 μg (n = 63) 18 μg (n = 155)
SAEs (total) 109 (60.2) 104 (53.9) 38 (55.9) 43 (68.3) 113 (60.8) 91 (58.7)
Cardiac 37 (20.4) 44 (22.8) 19 (27.9) 18 (28.6) 44 (23.7) 44 (28.4)
Vital status FAE (total) 38 (21.0) 34 (17.6) 11 (16.2) 8 (12.7) 41 (22.0) 34 (21.9)
Cardiac 12 (6.6) 8 (4.1) 3 (4.4) 3 (4.8) 15 (8.1) 9 (5.8)
General disorders† 6 (3.3) 6 (3.1) 1 (1.5) 1 (1.6) 6 (3.2) 3 (1.9)
On-treatment FAE (total) 36 (19.9) 28 (14.5) 11 (16.2) 6 (9.5) 31 (16.7) 30 (19.4)
Cardiac 13 (7.2) 9 (4.7) 3 (4.4) 3 (4.8) 11 (5.9) 9 (5.8)
General disorders† 4 (2.2) 3 (1.6) 1 (1.5) 0 (0.0) 3 (1.6) 2 (1.3)
Fatal MACE 15 (8.3) 10 (5.2) 5 (7.4) 3 (4.8) 13 (7.0) 11 (7.1)
Fatal MACE (including death unknown) 18 (9.9) 13 (6.7) 5 (7.4) 3 (4.8) 16 (8.6) 11 (7.1)
MACE 25 (13.8) 15 (7.8) 11 (16.2) 6 (9.5) 23 (12.4) 16 (10.3)
*First event did not lead to discontinuation. †SOC: general disorders and administration site conditions (death, sudden death, sudden cardiac death). FAE, fatal
adverse event, MACE, major adverse cardiovascular event, MI, myocardial infarction, SAE, serious adverse event, SOC, system organ class; UPLIFT®, Understanding
Potential Long-term Impacts on Function with Tiotropium.
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discontinuations: 27 in the placebo arm, 29 in the tiotro-
pium arm. Kaplan-Meier analysis revealed a trend to
later onset of the first cardiac failure event with tiotro-
pium compared with placebo (Figure 1C).
Mean treatment duration following the first cardiac
failure was 474.3 days (SD: 417.6) in the placebo arm
and 447.0 days (SD: 399.4) in the tiotropium arm.
Among those administered placebo who experienced
cardiac failure during the study, 60.8% subsequently ex-
perienced an SAE and 23.7% experienced a cardiac SAE.
In the tiotropium arm, 58.7% of patients subsequently
experienced an SAE and 28.4% experienced a cardiac
SAE (Table 1).
Following a cardiac failure event, vital status FAEs oc-
curred with similar frequency in both those who had re-
ceived placebo (22.0%) and those on tiotropium (21.9%)
(Table 1). On-treatment FAEs were experienced by
16.7% of patients in the placebo arm and 19.4% of pa-
tients in the tiotropium arm (Table 1).
Evaluation of events on treatment by MACE endpoints
did not suggest an increase in events with tiotropium
compared with placebo (Table 1; Additional file 2). For
patients experiencing cardiac failure, the incidence of
MACE was 12.4% in the placebo arm compared with
10.3% in the tiotropium arm. Fatal MACE affected 7.0%
of patients receiving placebo and 7.1% of patients treated
with tiotropium; the incidence of fatal MACE, including
death unknown, was 8.6% and 7.1%, respectively.Discussion
The UPLIFT® study confirmed the CV safety of tiotro-
pium over 4 years for the population included [10,21].
The extensive, long-term patient data generated from
the UPLIFT® study have allowed us to investigate retro-
spectively the potential impact of tiotropium versus pla-
cebo on the safety of patients experiencing the types of
cardiac events during the study that would have led to
exclusion at baseline. The analysis of SAEs or FAEs, in-
cluding cardiac deaths and death for unknown reasons,
in patients after experiencing cardiac arrhythmia, MI or
cardiac failure during the conduct of UPLIFT® does not
indicate any increase in total or cardiac SAEs or mortal-
ity with tiotropium HandiHaler® treatment compared
with placebo.
The findings should ameliorate the concerns raised by
Walker and colleagues regarding the generalisability of
the results of the UPLIFT® trial, based on their analysis
of a hospitalised population of patients with COPD in
New Zealand [18]. Although patients with unstable or
life-threatening cardiac arrhythmias, recent acute MI or
severe heart failure requiring hospitalisation were ex-
cluded from UPLIFT® (in line with most long-term
COPD trials designed to evaluate chronic benefit to risk
of pharmacotherapy), but they were not required to
withdraw from the study if such an event occurred. The
majority of these patients remained in the trial, even
though approximately 60% had an SAE and 20% had a
cardiac SAE, with similar incidences in the tiotropium
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these patients, we are able to show that tiotropium does
not increase the risk of total or cardiac SAEs or mortal-
ity compared with placebo in patients who have previ-
ously experienced serious cardiac events.
It should also be noted that the hospitalised popula-
tion described by Walker and colleagues [18] – in
which 38% would have been ineligible for UPLIFT® at
the time of discharge due to recent CV co-morbidity or
moderate to severe renal impairment – may not be rep-
resentative of the general COPD population. In a recent
epidemiological analysis from the Netherlands (mean
age 68 years), only 2.1% of patients starting treatment
with tiotropium HandiHaler® had a COPD-related hos-
pitalisation in the preceding year [22]. In addition, in an
analysis of an elderly Canadian population (aged ≥66 years),
only 9.8% were recently hospitalised for a respiratory
condition and only 1.3% of patients were hospitalised
for acute coronary syndrome, including MI, during the
6 months preceding the analysis [23]. Respective per-
centages were 0.2% for arrhythmias and 2.2% for heart
failure. These findings suggest that the incidence of the
conditions excluding patients from the initial inclusion
in the UPLIFT® study is relatively low.
This analysis has strengths and weaknesses. One obvi-
ous weakness is that it is a post-hoc analysis with no hy-
pothesis testing. However, the data from this analysis do
not suggest a safety issue in patients with the respective
cardiac conditions. Furthermore, a minority of patients
dropped out due to the first cardiac event. In general,
there was a trend towards fewer patients dropping out
in the tiotropium group, limiting potential bias in favour
of tiotropium. Strengths of the analysis are that it is
derived from a randomised, double-blind study, which
reduces the probability of bias in epidemiological ana-
lyses where effects arising from prognostic differences
among patient groups are a major concern. Finally, the
long, 4-year duration of UPLIFT® offered a unique op-
portunity to investigate the safety of tiotropium in pa-
tients with acute major cardiac events who remained in
the study.
From this post-hoc analysis of the UPLIFT® trial data,
we conclude that tiotropium HandiHaler® does not in-
crease the risk of cardiac deaths, deaths unknown or
other cardiac SAEs, following the occurrence of a car-
diac event. The findings add to the body of data support-
ing the use of tiotropium HandiHaler® in patients with
COPD, irrespective of pre-existing cardiac conditions.
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during UPLIFT® (on treatment + 30 days)*.
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